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Limited options for the treatment of cartilage damage have driven the development of tissue
engineered or cell therapy alternatives reliant on ex vivo cell expansion. The study of chon-
drogenesis in primary cells is difficult due to progressive cellular aging and senescence.
Immortalisation via the reintroduction of the catalytic component of telomerase, hTERT,
could allow repeated, longitudinal studies to be performed while bypassing senescent
phenotypes.
Methods
Three human cell types: bone marrow-derived stromal cells (BMA13), embryonic stem cell-
derived (1C6) and chondrocytes (OK3) were transduced with hTERT (BMA13H, 1C6H and
OK3H) and proliferation, surface marker expression and tri-lineage differentiation capacity
determined. The sulphated glycosaminoglycan (sGAG) content of the monolayer and spent
media was quantified in maintenance media (MM) and pro-chondrogenic media (PChM)
and normalised to DNA.
Results
hTERT expression was confirmed in transduced cells with proliferation enhancement in
1C6H and OK3H cells but not BMA13H. All cells were negative for leukocyte markers
(CD19, CD34, CD45) and CD73 positive. CD14 was expressed at low levels on OK3 and
OK3H and HLA-DR on BMA13 (84.8%). CD90 was high for BMA13 (84.9%) and OK3
(97.3%) and moderate for 1C6 (56.7%), expression was reduced in BMA13H (33.7%) and
1C6H (1.6%). CD105 levels varied (BMA13 87.7%, 1C6 8.2%, OK3 43.3%) and underwent
reduction in OK3H (25.1%). 1C6 and BMA13 demonstrated osteogenic and adipogenic
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differentiation but mineralised matrix and lipid accumulation appeared reduced post hTERT
transduction. Chondrogenic differentiation resulted in increased monolayer-associated
sGAG in all primary cells and 1C6H (p<0.001), and BMA13H (p<0.05). In contrast OK3H
demonstrated reduced monolayer-associated sGAG in PChM (p<0.001). Media-associated
sGAG accounted for55% (PChM-1C6) and74% (MM-1C6H).
Conclusion
In conclusion, hTERT transduction could, but did not always, prevent senescence and cell
phenotype, including differentiation potential, was affected in a variable manner. As such,
these cells are not a direct substitute for primary cells in cartilage regeneration research.
Introduction
Cartilage damage due to injury or degenerative disease represents a significant challenge to the
medical profession with limited treatment options available,[1]. Once compromised, this avas-
cular, aneural tissue containing relatively small numbers of largely quiescent cells[2] usually
fails to heal spontaneously, leading to long term tissue degradation[3]. This degradation is
associated with poor function, joint pain and ultimately prosthetic joint replacement; this pro-
cedure is performed every 1.5 minutes in Europe, mainly due to osteoarthritis[1], with 15% of
joint replacement surgeries being performed on those under 60 in the UK[4]. Although this
surgery is frequently successful, the limited lifespan of prosthetic joints makes them a poor
option for a younger demographic. Cell based therapies, which aim to promote intrinsic tissue
regeneration, or to replace the degenerated tissue with engineered chondral or osteochondral
constructs, are a promising alternative. To be successful these therapies need to recapitulate the
proteoglycan/sGAG rich extracellular matrix (ECM) and restore tissue biomechanical proper-
ties. To date, therapies have often resulted in symptomatic improvements for patients[5] how-
ever they have not consistently resulted in hyaline tissue regeneration[6] which may impact on
long term treatment efficacy.
Cell types currently under clinical investigation for cartilage repair include autologous
chondrocytes and mesenchymal stem/stromal cells (MSCs). Initially evaluated in cartilage
repair in 1994[7], autologous chondrocytes, with a mature native cartilage phenotype, are well
suited. However they are available in limited quantities from a constrained donor site where
tissue extraction may be associated with further donor site morbidity. They also require signifi-
cant ex-vivo expansion which is associated with rapid dedifferentiation and a loss of chondro-
genic phenotype[8]. Additionally there are as yet unanswered questions surrounding their
clinical application at a time when, in older patients, many of the cells within the cartilage may
be becoming senescent or apoptotic, particularly once the tissue is showing signs of osteoarthri-
tis[9]. Chondrocyte senescence is increasingly implicated in the disease pathology with
increased senescence associated β Galactosidase (SA βGal) activity in cells surrounding articu-
lar cartilage lesions, reduced mitotic activity and reduced telomere lengths, all correlating with
increasing age[10].
As an alternative to chondrocytes, multipotent[11] mesenchymal stem/stromal cells, as
described by Friedenstein et al[12], offer potentially greater proliferation, a more flexible
response to differentiation cues and the prospect of an allogeneic therapy due to their immuno-
modulatory properties[13]. Unlike chondrocytes MSCs are also available from numerous tis-
sues including several that would otherwise be discarded[14], removing the requirement for
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invasive surgery and healthy tissue removal. Both cell types have an adequate proliferative
capacity for autologous cell therapies but show widespread variation in proliferation and then
efficacy of differentiation potential between donors[15], particularly as the donor age increases
[16]. Human embryonic stem cells (hESCs) have greater still proliferative and differentiation
possibilities, due to their properties of self-renewal and pluripotency[17]. However numerous
technical challenges concerning uniformity of differentiation and purity of cell populations
must be resolved before these cells can be used safely due to the inherent capacity of undiffer-
entiated cells to form teratomas. Despite these difficulties hESC derived cells are now entering
early phase clinical trials[18].
A major hurdle to the use of any primary cell type is the progressive onset of replicative
senescence. One cause of senescence is the shortening of telomeres, the TTAGGG nucleotide
sequence repeats which cap linear mammalian chromosomes, preventing chromosomal degra-
dation and fusion during mitotic DNA replication. Continued telomere erosion to a critically
short length causes cells to become senescent as a result of DNA damage signalling events[19].
Additionally, more recently, telomeres have been proposed to be the repositories of irreparable
DNA double strand breaks, especially in non-dividing cells owing to the reduced capacity of
telomeres to engage non homologous end joining DNA repair[20][21]. Furthermore ectopic
telomerase expression has been reported to slowly resolve the DNA lesions by an as yet
unknown mechanism[22]. In vivo, endogenous telomerase expression is detectable only in
stem and early progenitor cells, somatic cells in some rapidly renewing tissues and in cancerous
cells, in vitro expression appears more restricted and is only consistently found in hESCs and
cancer cells[23]. It has been demonstrated that replicative senescence can be avoided by the re-
expression and activity of the telomerase reverse transcriptase catalytic subunit, hTERT[24–26]
which can support the maintenance of telomere length whilst also preserving or even enhanc-
ing cell function[27].
The aim of this study was to compare the phenotype, particularly chondrogenic potential,
of MSCs, chondrocytes and hESC derived MSC-like cells along with their corresponding
hTERT transduced cell lines. hTERT was successfully introduced to all three cell types and pre-
vented replicative senescence in chondrocytes and hESC derived MSC-like cells. Changes in
cell phenotype were found in all three transduced cell lines including altered morphology,
modifications in cell surface marker expression and alterations in differentiation capacity.
Notably, transduced human chondrocytes lost chondrogenic capacity as a consequence of
immortalisation.
Materials and Methods
Cell isolation and culture
Commercially sourced whole bone marrow aspirate (Lonza) was seeded at a density of 1x105
mononuclear cells/cm2 in tissue culture flasks pre-coated with 10 ng/ml fibronectin (Sigma) in
PBS. Cells were seeded in high glucose DMEM (4.5 g/L glucose) supplemented with 5% (v/v)
foetal bovine serum (FBS), 1% (v/v) L-Glutamine (L-Glut), 1% (v/v) non-essential amino acids
(NEAA) and 1% (v/v) Penicillin/Streptomycin/Amphotericin B (Lonza) and maintained in a
2% O2 atmosphere, to improve proliferation and chondrogenic potential[28]; a 50% media
change was performed after one week and 100% media change at two weeks[29]. Following iso-
lation MSC cells were designated BMA13. BMA13 and commercially sourced primary human
articular (knee/hip) chondrocytes, OK3 (PromoCell), underwent routine media changes twice
weekly with maintenance media (MM) consisting of DMEM supplemented with 10% (v/v)
FBS, 1% (v/v) L-Glut, 1% (v/v) NEAA and 4 ng/mL bFGF (Peprotech) to enhance proliferation
[30]. Embryonic stem cell clonally derived progenitor cells 1C6 were derived from the H1
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embryonic stem cell line as described by Forsyth et al[31]. Cells were cultured in a MM of
KO-DMEM (Life Technologies) supplemented with 10% (v/v) FBS, 1% (v/v) L-Glut, 1% (v/v)
NEAA, 4 ng/mL bFGF and 100 nM dexamethasone (Sigma). A complete media change was
performed twice weekly. All cells were sub-cultured enzymatically at confluence using 0.25%
trypsin/EDTA (Lonza). Population doublings (PD) of cells were estimated based upon the split
ratio of cells at sub-culture, cells were assumed to be senescent when the cumulative PD pla-
teaued and cells no longer achieved 100% confluence after at least 30 days in culture.
Retroviral transduction with hTERT
To increase cellular replicative potential, hTERT retroviral transduction was performed in all
three cell types. BMA13 and OK3 cells were seeded at 5x104 cells per well and 1C6 at 2.5x104
per well in 6 well culture plates and cultured for 48 hours prior to infection. The Phoenix A
packaging cell line was infected with either pBABE-hTERT or pBABE (empty vector) retroviral
vectors[24]. Supernatant containing virus was filtered with a 0.45 μm syringe filter and used to
spinfect target cells in the presence of 5 μg/ml polybrene by centrifuging the pre-gassed (10%
CO2/90% air) and sealed plates for 1 hour at 10 g at 32°C. After 6 hours the infection process
was repeated with fresh viral supernatant. Selection of successfully transduced cells was begun
24 hours after infection with medium supplemented with G418 (Sigma) at 1 mg/mL for two
weeks with hTERT, empty vector and untransfected, plates.
Gene expression analysis
Expression of hTERT was determined using reverse transcription polymerase chain reaction
(RT-PCR). RNA was extracted from cells using the RNEasy minikit and QIAshredder homoge-
nisation minispin columns (Qiagen) following the manufacturer’s protocol. RNA extracts were
amplified using one step RT-PCR with the SuperScript III One-Step RT-PCR Platinum Taq
HiFi kit (Life Technologies). RT-PCR was carried out with custom primers (Life Technologies)
for the housekeeping gene β-Actin, and hTERT with primer sequences: β-Actin: forward:
GCCACGGCTGCTTCCAGC, reverse: AGGGTGTAACGCAACTAAGTC, hTERT: forward:
GCAGCTCCCATTTCATCAGC, reverse: AGGATGGTCTTGAAGTCTG. RT–PCR products
were separated and viewed on 2% agarose gels with 0.5 μg/mL ethidium bromide (Sigma).
Flow cytometry immunophenotyping
Cells were trypsinised, counted and re-suspended in flow cytometry buffer (R & D systems) for
15 minutes and approximately 1X105 cells aliquoted into 1.5 mL microcentrifuge tubes, centri-
fuged at 300 g for 10 minutes and the supernatant discarded. Phycoerythrin conjugated anti-
bodies (CD14, CD19, CD34, CD45, CD73, CD90 and CD105, HLA-DR, IgG1 and IgG2a
isotype controls (Miltenyi Biotech)) in flow cytometry buffer were used to re-suspend cell pel-
lets followed by incubation in the dark at 4°C for 10 minutes. A 10X volume of buffer was
added and cells centrifuged at 300 g for 10 minutes, supernatant discarded and the cells re-sus-
pended in flow cytometry buffer. At least 50,000 events were acquired on a Beckton Dickinson
FSC500 flow cytometer. Percentage positive events were determined using gates to exclude
99% of the appropriate isotype control events.
Senescence associated β-Galactosidase staining
A senescent phenotype was confirmed by SA βGal staining[32] using an SA βGal histochemical
staining kit (Sigma) according to the manufacturer’s protocol. Staining was performed for 16
hours at 37°C after which the staining mixture was removed and the cells washed with PBS.
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Cells were counterstained with haematoxylin prior to the acquisition of photomicrographs and
cells in 4 field of view for each cell type were counted for SAβGal activity using Fiji image anal-
ysis software[33].
Tri-lineage differentiation of cells
To determine differentiation potential cells were seeded at 5x104/cm2 in standard proliferation
media overnight to allow attachment after which media were changed to differentiation media.
Cells were then cultured in differentiation media for 20 days with media changes twice weekly.
Osteogenesis was induced in cells using media supplemented with 50 μM ascorbic acid, 10 mM
β-glycerophosphate and 0.1 μMdexamethasone before being fixed with 95%methanol and stain-
ing with 1% alizarin red S for calcium deposits (Sigma). Adipogenesis was induced with 0.5 μM
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, 10 μg/mL insulin and 0.1 mM indometh-
acin. Cells were fixed with 4% (w/v) paraformaldehyde in PBS, washed with 60% (v/v) isopropanol
before being stained with oil red O for intracellular lipid droplets. Chondrogenic differentia-
tion was induced using pro-chondrogenic media (PChM) which consisted of basal media with
reduced FBS (1% (v/v) FBS) further supplemented with, 1% (v/v) ITS, 1% (v/v) sodium pyru-
vate, 0.1 μM dexamethasone, 50 μM ascorbic acid, 40 μg/mL L-proline (Sigma) and 10 ng/mL
TGF-β3. Cells were fixed with 95% methanol and stained with alcian blue (pH 1.5) overnight
for sulphated glycosaminoglycan accumulation.
Sample preparation for DNA and total sGAG analyses
Chondrogenic differentiation was induced using PChM as described. Cells were seeded in
24 well tissue culture plates in MM and incubated overnight to allow attachment. MM were
then substituted with fresh MM or PChM and changed regularly throughout the experiment,
all media were collected for sGAG analysis.
At days 0 and 20 media was removed and cell monolayer digested with 250 μg of proteinase
K in 200 μL of 100 mM ammonium acetate for 24 hours at 60°C. Samples were precipitated
with ice cold ethanol overnight at -20°C, centrifuged at 13200 rpm to pellet the precipitate and
the ethanol supernatant discarded. Pellets were allowed to dry then re-dissolved in 125 μL of
100 mM ammonium acetate for PicoGreen and DMMB analysis.
Collected media was treated with 250 μg of 2.5 mg/mL proteinase K per mL overnight fol-
lowed by the addition of 1 mL of ice-cold ethanol and precipitation at -20°C overnight. Precipi-
tate was pelleted by centrifugation at 17,000 g for 15 minutes and the ethanol supernatant
discarded before the pellet was dried and re-dissolved in 125 μL of 100 mM ammonium acetate
for DMMB analysis.
Total DNA quantification by PicoGreen double stranded DNA assay
The Quant-iT PicoGreen double stranded DNA assay (Life Technologies) was carried out
according to the manufacturer’s protocol. Duplicate sample aliquots were diluted 1 in 10 in TE
buffer in 96 well microplates prior to incubation with PicoGreen working solution in the dark.
Plates were read using a Synergy 2 plate reader (Biotek) (excitation 480 nm, emission 520 nm).
Concentrations were determined using a lambda DNA calibration curve.
Total sGAG quantification by DMMB assay
Samples dissolved in 100 mM ammonium acetate were used for DMMB total sGAG quantifica-
tion[34] and were aliquoted in duplicate into a 96 well microplate followed by transfer into a
Synergy 2 plate reader. An automated dispense unit was then used to dispense 200 μL of
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DMMB solution (16 mg DMMB, 0.76 g glycine, 0.595 g NaCl, 23.75 mL 0.1 M HCl, distilled
H2O to 250 mL) to a single well followed by determination of the absorption at 530 nm. All
wells were processed in this manner to maximise reproducibility and minimise the potential
for precipitation of the DMMB-sGAG complex.
Statistical analysis
Data are expressed as mean ± standard deviation. Statistical analysis of SAβGal staining was by
one way ANOVA with Tukey’s multiple comparisons. Statistical analysis of sGAG production
was by repeated measures two-way ANOVA with Bonferroni post-tests of chondrogenic sup-
plemented samples compared to non-supplemented controls using Graphpad Prism 6.01,
Graphpad, San Diego California, USA. Results were deemed to be statistically significant when
p<0.05.
Results
The impact of hTERT transduction
Following hTERT transduction RT-PCR confirmed hTERT expression in all three transduced
cell types, whilst expression was absent in the non-transduced cell populations and the empty
vector transduced cells BMA13EV and 1C6EV (Fig 1A). Expression in transduced cells was
detected following initial expansion of transduced cells in culture post transduction, and was
maintained in continuous culture.
Optical phase contrast microscopy was used to examine the cell morphology of parental
and transduced cells. 1C6H (Fig 1C), 1C6EV (Fig 1I) and OK3H (Fig 1H) and BMA13EV (Fig
1F) retained similar morphologies post transduction to their respective non-transduced cells
1C6 (Fig 1B) and OK3 (Fig 1D). 1C6 and 1C6H both proliferated as closely aligned, colony-
like clusters of small bipolar cells. OK3 and OK3H had a fibroblastic morphology consistent
with that of dedifferentiated chondrocytes. However, changes were observed with BMA13H
(Fig 1E) in comparison to BMA13 (Fig 1F). BMA13 had the expected spindle shaped MSC
morphology eventually forming closely aligned colonies, however, BMA13H whilst initially
resembling the parental cells later presented as a more heterogeneous population with cells fre-
quently having a larger more flattened morphology with multiple cell processes.
hTERT transduction conferred gains in proliferative capacity in 1C6H, where cells prolifer-
ated for> 100 PD compared to 60 PD in 1C6 cells. OK3H achieved>60 PD compared to 20
PD with OK3 cells, although OK3H cells displayed a substantial period of reduced prolifera-
tion, at around 35 PD, followed by recovery to earlier rates. BMA13H proliferation ceased after
only a slightly increased number of PD to PD31 compared to PD23 achieved with BMA13.
Expansion with cryopreserved BMA13H (cryopreserved at PD8) resulted in a further reduced
capacity for proliferation to levels matching BMA13 so further experiments were performed
with BMA13H cells at PD16-20. 1C6H and OK3H have both continued to proliferate beyond
PD107 and PD60 respectively (S1 Fig). Cells were stained for SA βGal activity (Fig 2A–2M)
which was then quantified (Fig 2N–2P); all early PD non-transduced cells stained weakly for
SA βGal, this was significantly (p0.0001) increased in late PD non-transduced and empty
vector cells with these strongly stained cells often also having an altered morphology whereby
cells were larger and rounder. Later PD hTERT transduced 1C6H and BMA13H had minimal
staining that was comparable to early PD non-transduced cells. As BMA13H were stained at a
slightly lower PD than BMA13 at PD21 an earlier culture of BMA13, at PD17, was also stained
to ensure that senescence had not rapidly increased in BMA13 within the last few PD. Quantifi-
cation of the cells at PD17 resulted in 60.5 ± 7.9% positive staining, significantly higher
(p0.0001) than basal levels and PD 18 BMA13H. OK3H cultures displayed both SA βGAL
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positive and negative cells resulting in a population that stained significantly (p0.01) higher
than parental low PD cells but remained significantly lower than late PD parental cells
(p0.0001).
Cell immunophenotype
All cell types were analysed by flow cytometry for expression of haematopoietic (CD14, CD19,
CD34, CD45 and HLA-DR) and mesodermal (CD73, CD90, CD105) cell surface markers (Fig
3).
All cells were negative (<2% positive compared to the isotype control) for leukocyte mark-
ers CD14, CD19, CD45 and the haematopoietic cell marker CD34 with the exception of slight
positivity for CD14 in OK3 (9.4%) and OK3H (3.4%). HLA-DR expression was also absent in
Fig 1. hTERT expression and impact on cell morphology. (A) Expression of the housekeeping gene ACTB and hTERT determined by RT-PCR in cells
following recovery post transduction and with expansion in continuous cell culture. (B-I) Phase contrast micrographs of cells in monolayer culture pre- (B, D
and F) and post- (C, E and G) transduction with hTERT or with empty vector (F and I) Scale = 150 μm, exact PD as indicated in image.
doi:10.1371/journal.pone.0133745.g001
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all but BMA13 cells where 84.8% of events were positive. The BMA13 cells were cultured to
passage 4 in the presence of bFGF and similar HLA-DR positive staining has been noted in
these conditions by Sotiropoulou et al[35]. CD73 expression was high in all cell types (>98%)
however variation in immunophenotype was noted with CD90 and CD105 according to both
cell type and immortalisation status. BMA13 expression of CD90 and CD105 was 84.9% and
87.7%, respectively, whereas transduced BMA13H maintained CD105 expression (87.1%) but
displayed reduced CD90 expression (33.7%). 1C6 cells expressed moderate CD90 (56.7%),
which was reduced post-immortalisation (1.6%), and low CD105 (8.2% vs. 6.8% (1C6H). OK3
and OK3H displayed high expression of CD73 and CD90 (>94%) and moderate expression of
CD105 (43.1%) which was reduced inOK3H (25.1%).
Cell differentiation
Soluble media supplements were used to drive differentiation in cells followed by fixation, his-
tological staining and imaging (Fig 4).
Fig 2. The effect of hTERT expression on senescence associated βGalactosidase (SA βGal) activity. (A-M) SA βGal activity in early and late PD non-
transduced and empty vector transduced cells, and late PD hTERT transduced cells. Scale = 100 μm, exact PD as indicated in image. (N-P) Percentage of
cells stained positively for SA βGal activity, mean n = 4 ± SD. (** p0.01, **** p0.0001)
doi:10.1371/journal.pone.0133745.g002
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Under the influence of differentiation supplements 1C6 and BMA13 cells underwent osteo-
genesis, with positive alizarin red staining of mineralised areas; chondrogenesis, indicated by
alcian blue sGAG staining; and adipogenesis, with oil red O stained lipid vesicles. OK3 cells did
not produce mineralised matrix, stained strongly for sGAG and showed some accumulation of
lipids. 1C6H and BMA13H also differentiated however staining of mineralised matrix and lip-
ids appeared reduced. As with OK3, OK3H did not mineralise under osteogenic conditions,
however the response to pro-chondrogenic supplements was greatly reduced compared to
OK3 with little sGAG staining, along with an apparent increase in lipid accumulation.
Quantification of sGAG production during in vitro chondrogenesis
sGAG associated with both monolayer and culture media was compared in hTERT transduced
and parental cell types following 20 days of culture in the presence of MM or PChM. All cul-
tures displayed an increase in total sGAG after 20 days in culture compared to day 0 values
irrespective of culture media conditions (Fig 5A and 5C). Larger total sGAG increases were
detected when cells were cultured in MM than PChM in all cases excepting BMA13, with
increases in sGAG in MM ranging from 4.4 fold over day 0 values in 1C6H to 30.9 fold in OK3.
This compared to values in PChM ranging from 3.1 fold in OK3H to 14.7 fold in BMA13. All
three non-transduced cell types had greater fold increases and total sGAG production than
their corresponding hTERT transduced cell types.
By day 20 PChM resulted in greater amounts of monolayer associated sGAG (p<0.001) in
all cases except OK3H where monolayer sGAG was higher in MM (p<0.001). Concomitantly
Fig 3. Flow cytometry analysis of cell surfacemarker expression. (A) Expression of surface markers CD14, CD19, CD34, CD45, HLA-DR, CD73, CD90,
CD105 (filled) with relevant isotype control (unfilled). (B) Quantification of the percentage of positive events compared to the relevant isotype control. Markers
set to exclude 99% of isotype control events; 4x104events were collected per sample. OK3 was tested at PD10, OK3H at PD50, BMA13 at PD6, BMA13H
at PD18, 1C6 at PD44 and 1C6H at PD118.
doi:10.1371/journal.pone.0133745.g003
Fig 4. Tri-lineage differentiation capacity of cells over 21 days.Cells were cultured in monolayer for 21 days in the presence of the appropriate pro-
differentiation supplements followed by fixation and staining. Osteogenic samples were stained with alizarin red for calcium deposits, scale = 150 μm.
Chondrogenic samples were stained with alcian blue for SGAGs, images are from 1 well of a 24 well plate. Chondrogenic medium frequently caused cells to
partially or fully separate from the substrate and contract into pellet-like structures. Adipogenic samples are stained with oil red O for lipid droplets,
scale = 80 μm. Images of controls cells cultured in standard maintenance media and stained as appropriate are inset for comparison.
doi:10.1371/journal.pone.0133745.g004
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Fig 5. Quantification of sulphated glycosaminoglycan (sGAG) production and retention. (A) DMMB quantification of sGAG in both the media fraction
and monolayer fraction after culture in either MM (-) or PChM (+) for 20 days. (B) Normalisation of sGAG to DNA at Day 20 in MM (-) or PChM (+). (C) Fold
change in sGAG at Day 20 compared to levels determined at Day 0 in monolayer (left), media (middle) and in total (right). (D) Fold change in DNA normalised
hTERT Immortalisation and Chondrogenesis
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the media associated fraction was significantly reduced in PChM in all but BMA13. The pro-
portion of total sGAG associated with the monolayer by day 20 ranged from 3.0% (OK3H) to
25.2% (1C6H) in MM and 8.4% (OK3H) to 44.5% (1C6) in PChM.
The BMA13EV response was comparable to the primary cell response (S2 Fig) with a signif-
icant (p0.001) increase in monolayer associated sGAG concurrent with a significantly
decreased media associated sGAG, resulting in an overall reduction in total sGAG in PChM. In
contrast 1C6EV had a much lower response although this still followed the same trends with
only a 1.4 fold increase in monolayer associated sGAG with the difference between the sGAG
monolayer content in the two media types not reaching significance.
As with absolute levels of sGAG, higher normalised monolayer associated sGAG (p<0.001)
was found in all cells except OK3H, concurrent with a decreased media associated fraction, in
PChM compared to MM (Fig 5B and 5D). Normalisation of sGAG to DNA (μg/μg) enables
changes in sGAG due to altered cell numbers as a result of cell proliferation or cell death to be
separated from changes in sGAG synthetic activity. 1C6 and BMA13 had large fold increases
in absolute monolayer associated sGAG but low normalised sGAG indicative of a high degree
of cell proliferation associated with the increased sGAG. In contrast high normalised sGAG
compared to relatively low absolute levels were seen in 1C6H in PChM. This was as a result of
a lower DNA content (below day 0 levels), and not solely as a result of high sGAG synthesis,
leading to a correspondingly large fold change in normalised monolayer associated sGAG.
Discussion
This study aimed to quantify the sGAG produced, a key measure of chondrogenic response, in
a simple pro-chondrogenic in vitro environment using three alternative cell sources: MSCs,
chondrocytes and ESC derived cells, all with potential for cartilage tissue engineering applica-
tions. The ECM glycosaminoglycan content represents a responsive marker for chondrogenesis
due to its relatively rapid in vivo turnover rate compared to other cartilage matrix components
[36]. We have previously subjected the parental cell types OK3, 1C6, and hMSC to RT-PCR
analysis for several genes, including the COL2A1, transcript and found a poor correlation
between chondrogenic induction, gene expression and ECM protein content [37], as have oth-
ers[38].
We investigated the immortalisation of these cells with the catalytic subunit of telomerase
[39–41] to improve their longevity and usefulness as a research tool. The expression of the cata-
lytic subunit, hTERT, rather than the other components of telomerase (hTR and TP1) has been
determined to be the limiting step in telomerase activity with strong correlation between
hTERT expression and telomerase activity[42]. This immortalization approach has particular
applicability for cartilage based cell therapies as in addition to the phenomenon of replicative
senescence, primary chondrocytes undergo rapid de-differentiation during in vitro culture
with a corresponding loss of phenotype[8][43] including reduced expression of chondrocyte
associated genes[44] and reduced responsiveness to pro chondrogenic signals[45], making any
long term study of these cells challenging.
Low levels of telomerase activity have occasionally been detected in human chondrocyte
and MSC cell cultures[46][47]. Our results were in accordance with the majority of previous
literature and telomerase expression was absent in the primary non-transduced MSCs BMA13
[48–52], chondrocytes OK3[53], and embryonic derived 1C6[31]. hTERT transduction
sGAG at Day 20 compared to Day 0 in monolayer (left), media (middle) and in total (right). Bold line at a fold change of 1 indicates no change compared to
Day 0 levels. # p<0.05, + p<0.01, *p<0.001 (mean n = 3 ±SD). Experiments were performed at OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16, 1C6
PD 42 and 1C6H PD84.
doi:10.1371/journal.pone.0133745.g005
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resulted in lasting hTERT gene expression in all three cell types. However, despite this, we
noted a variable response with respect to proliferative potential where 1C6H was the only cell
type to undergo uninterrupted proliferation. The minimal changes in proliferative capacity
seen in BMA13H are in contrast to most other publications reporting successful immortalisa-
tion of MSCs[54–56] although some report similar results to ours with a small gain in prolifer-
ation capacity but not immortalisation[57]. The previous track record for immortalisation
success indicates that the cessation of growth in our cells may be due to a mechanism other
than telomere shortening. A strong candidate in our case would be oxidative stress; the cells
were conditioned to a 2% oxygen environment having been recovered and expanded in 2%
however the transduction and selection procedures were performed at a standard ambient oxy-
gen level (21%) exposing the cells to a significant period of hyperoxia. Oxidative stress during
exposure to higher ambient O2 levels is a known risk factor for stress induced cellular senes-
cence[58,59]. The 1C6 cells are known to be particularly sensitive to increased oxygen levels
[31]; 1C6EV was observed to senescence prematurely in comparison to 1C6H despite both
having been exposed to the same hyperoxic environment during transduction. However the
presence of TERT has been demonstrated to improve cellular resistance to stressors via a non-
canonical mechanism that is independent to telomere lengthening[60].
There are a limited number of reports describing chondrocyte immortalisation, particularly
in human cells. Earlier experiments used viral proto-oncogenes including the simian virus 40
large T antigen (SV40-Tag)[61] to immortalise cells and described varying impact on cell phe-
notype and a complex inverse relationship between cell proliferation and ECM synthesis,
whereby only slowly proliferating cells exhibited chondrogenic ECM synthesis[62][63].
Immortalisation of chondrocytes with hTERT has been described, with assessment of semi-
quantitative changes in aggrecan and collagen II gene expression. However, ECM formation
via the production and secretion of proteoglycan or proteins was not determined. Furthermore,
although the cells appeared to retain some chondrogenic capacity aggrecan and collagen II
expression were reduced compared to control chondrocytes[53]. However, the immortalisation
process in chondrocytes may be more complex as others have determined a requirement for
secondary transduction with human papillomavirus 16 oncogenes E6 and E7[64]. In low oxy-
gen culture conditions similar to those employed here only one of three lines gained prolifer-
ative potential following hTERT transduction despite evidence of extended telomeres in all
three[65]. These results along with the extended pause or “crisis period” experienced by OK3H
suggest that a secondary event allowing bypass of p53 or p16ink4a responses may have occurred
during OK3H culture to allow continued proliferation, although further experiments will be
required to determine this.
SA βGAL, a reported marker for senescent cells[32], in our samples resulted in the expected
higher level of staining of increasing numbers of cells in cultures approaching their maximum
number of population doublings. However, we observed that there was a low background level
of activity in both earlier PD OK3 and BMA13, and more notably, high levels in OK3H
although this was in conjunction with a population of cells with no detectable SA βGAL activ-
ity. It is possible that the OK3H is a mixed population with some cells undergoing senescence
but alternatively it is well known that there are multiple culture conditions where SA βGAL, a
lysosomal β-galactosidase[66], is found in proliferating cell populations including cells prolifer-
ating under stress and in regions of cell confluence[67][68]. The presence of SA βGAL activity
despite ongoing proliferation is further evidence that mechanisms other than telomere length-
dependent replicative senescence are active in our cultures. Similar results were found by Zhu
et al [69] transfection with both hTERT and CDK4 and further optimisation of culture condi-
tions was necessary to produced differentiation competent immortalised muscle satellite cells
[69].
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There are no unique markers for the classification of cells as MSCs and, of necessity, MSCs
are defined by a collection of cell surface markers and physical features. Specifically in 2006 a
set of minimal criteria guidelines for the definition of cells as MSCs was published by Dominici
et al[70] and this has since been used in many studies. This statement of the position of The
International Society for Cellular Therapy specified that MSCs should be plastic adherent;
express CD73, CD90 and CD105 and concomitantly lack expression of CD14 or CD11b, CD19
or CD79, CD34, CD45 and HLA-DR; and have tri-lineage mesodermal differentiation capacity
[70]. The BMA13 MSCs that were used in this study expressed CD73, CD90 and CD105 and
lacked expression of CD14, CD19, CD34 and CD45; however, moderate expression of
HLA-DR was found. Up-regulation of HLA-DR expression has been observed previously on
MSCs, more so when cells were isolated from whole bone marrow aspirate rather than sepa-
rated mononuclear cells, and particularly in response to exposure to bFGF[71][72]. Interest-
ingly we found that OK3 chondrocytes expressed CD73, CD90 and CD105, expression of MSC
markers on chondrocytes has been reported previously[8][73] with a greatly increased expres-
sion of CD90 in response to monolayer culture[8]. Alternatively it has been proposed that
these cells may be representative of a chondroprogenitor or MSC like cell type present within
cartilage[73]. In addition to variable proliferation responses we also noted changes in immuno-
phenotype linked to hTERT. CD90 expression was reduced in both BMA13H and 1C6H and
CD105 was reduced in OK3H when compared to parental cells. CD73, CD90 and CD105
expression decreases with increased passage number in MSCs[74] so these changes may be
indicative of a loss of MSC phenotype in BMA13H. A reduction in CD90 with increasing pro-
liferation following transduction with CD90 has also been noted in human adipose derived
stem cells[75].
During in vitro culture cells synthesise and secrete ECMmolecules including sGAG con-
taining proteoglycans to fill intercellular spaces[76]; our investigation found that all cell types,
in pro-chondrogenic conditions induced by TGF-β3[77] or not, produced sGAG in measurable
quantities. Interestingly total sGAG was generally determined to be higher in cells exposed to
MM than in PChM, where much of the sGAG was found in the media rather than in associa-
tion with the monolayer. Reports of sGAG quantities in media during in vitro culture vary
ranging from negligible amounts[78] to a large fraction (35–90% depending on culture condi-
tion) of the total sGAG produced[79]. Media sGAG has been used as a proxy for total sGAG
production[80] however our results do not support this, as we found large cell type dependent
differences in the proportion of retained versus secreted sGAG. Evidence provided by others
indicates that the losses to the media from the monolayer are probably as a result of the inabil-
ity of the ECM to retain the proteoglycan and sGAG which then diffuse into the media[79],
however proteoglycan degradation due to catabolic activity cannot be ruled out. Transduction
with hTERT had a particularly detrimental effect on monolayer associated sGAG with OK3H
in both absolute and normalised terms. This may be reflective of the particular difficulties that
seem to be associated with chondrocyte transduction[64][65]. The transduction procedure is
lengthy and cells continue to proliferate, and therefore dedifferentiate, during this process and
may have passed a critical point for re-differentiation. The cells are also polyclonal, polyclonal
expansion favours selection of rapidly growing cells over those with more favourable differenti-
ation properties[81]; clonal expansion and colony characterisation and selection may enable
the selection of a subpopulation of cells with a greater proliferative capacity.
To enable rapid assessment of the multiple cell types described herein experiments were
performed in monolayer culture however it is accepted that a three dimensional environment
can provide a more pro-chondrogenic influence[82][83]. As such further investigations are
underway to determine whether a pellet culture system can restore greater chondrogenic
capacity to our hTERT transduced cells.
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Conclusion
To regenerate articular cartilage, transplanted cells must produce large quantities of sGAGs
that are retained within the area of damaged tissue. All three primary cell types assessed herein
produced and retained significant amounts of sGAG in association with the monolayer in
response to a pro-chondrogenic influence. Two (1C6H and BMA13H) of three hTERT trans-
duced cell types exhibited similar responses to non-transduced cell types when sGAG was nor-
malised to DNA level so may well have in vitro application as chondrogenic cell lines where
large numbers of cells are required. However in contrast, the hTERT transduced chondrocyte
line OK3H performed poorly in response to PChM and had no increase in sGAG retained in
the monolayer. In all three hTERT lines cell immunophenotype differed from parental cell
types. These findings indicate that whilst hTERT transduction can be useful in prolonging cell
proliferation, its application may be associated with complex changes in cell phenotype and a
loss of differentiated cell function can be induced in a variable and cell specific manner. In
future, with further interventions to circumvent the problems we have identified herein, telo-
merised cells may still be a viable alternative.
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